Our Platform

Advancing the opportunity for a Best in Class Metabolic Disorder platform

LADA

PRM A activates an immune response on the alpha cell to release glucagon. It is also expressed on the Beta cell, K and L cells. Our breakthrough preclinical data in Hypoglycemia lead us to this pathway. We are now advancing a novel undisclosed therapy to treat Latent Autoimmune Diabetes in Adults with an estimated patient population of 100 million people compromised of 10% of people living with Diabetes.

Obesity

A novel undisclosed Oral treatment for Obesity.  We have target validation for a once daily oral Obesity treatment that may enable a new way to treat millions of people with Obesity.  Our new mechansim of action supports a target product profile that is safe, accessible, affordable and oral.  We are advancing INDe studies to provide a clinical candidate that will be highly differentiated.

Diabetes

We have differentiated preclinical data on several of our candidates in mono and fixed dose Combination therapy showing remarkable glucose lowering and synergystic effects.  These studies were conducted in acute and chronic studies over multiple relevant animal models.

NASH

Our discovery program includes proof of concept mechanistic studies over several of our candidates that showed unique liver activation that may lend itself to a novel therapy in NASH. This encouraging data is further supported by what we know about the target.

CVD

Alpha cell and Beta cell dysfunction is associated with cardiovascular disease. Our novel mechansim of action and molecular library may offer insight into intervention through pathways not previously explored.

Neuro

Our IP position covers GPR119 dysregulation which may address certain neurodegenerative conditions. As we explore our highly targeted molecular library and new mechanism of action we plan to advance candidates.

Oncology

Metabolic dysregulation can lead to certain cancers. Our new mechanism of action may enable the development of therapeutics to treat cancers via novel pathways that our candidates activate.

01

GPCR Agonists

The company has utilized smart drug discovery techniques, contracting teams of chemists and biologists who have leveraged new information and tools to more rationally develop interventions for targeting the complex pathology of Multiple Metabolic Disorders.

02

Design Strategy

Pramana has focused its design strategy on novel and proprietary structures to differentiate its GPCR agonists. This strategy has led to the discovery of potent and selective small molecules for Metabolic disorders treatment.

03

Hypoglycemia

Pramana has advanced its lead candidate PRM A for the prevention of Hypoglycemia. PRM A is highly targeted and acts a "smart regulator" to glucagon imbalance.

04

Utilization

Overseen by a world class scientific team, Pramana has utilized their deep expertise in the development of its potent, selective and proprietary wholly owned portfolio.

Our proprietary class of small molecules targets  Diabetes and Metabolic disorders

Advancing the Potential of a Best in Class Metabolic Disorder platform

Sitemap
HomeAbout UsPlatformPipelineMarketTeam
Contact
#602-570 Granville StreetVancouver, B.C. V6C 3P11-866-729-3511
Copyright © 2022 Pramana